ClinicalTrials.Veeva

Menu

Digital Treatment of Irritable Bowel Syndrome (IBS) (DIGIBS)

H

Haukeland University Hospital

Status

Active, not recruiting

Conditions

IBS - Irritable Bowel Syndrome

Treatments

Behavioral: Module 1
Behavioral: Module 3
Behavioral: Module 5
Behavioral: Module 2
Behavioral: Module 4

Study type

Interventional

Funder types

Other

Identifiers

NCT06117865
2023-630038

Details and patient eligibility

About

The aim of this work is to identify whether the digital treatment program Mage-tarmskolen has an effect on patients with IBS. Our secondary objectives is to address multiple aspects of digital treatmtent success of the different modules. The patients will be randomized to one of four arms and will be delivered different kinds of digital treatment. All patients will have access to ask questions to a registered dietitian. Primary end point is the proportion of patients with treatment success in the low FODMAP, behavioral therapy or both groups, versus the patient education group (sham). Treatment effect is defined as an improvement of 50 points or more on the IBS severity scoring system at 3 months after treatment start compared to the score before treatment.

Enrollment

728 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Diagnosed with IBS in the primary or secondary healthcare service.
  • Patients aged 18-70 years with IBS defined by the Rome IV criteria: Recurrent abdominal pain, on average at least 1 day per week during the previous 3 months, that is associated with two or more of the following: i) Defecation, either increased pain or pain relief, ii) Change in stool frequency, iii) Change in stool form (appearance)
  • All participants >50 years: Colonoscopy within the last 5 years prior to study entry excluding other pathology
  • Bank-ID and access to tablet, PC or smart phone.
  • No known presence of: symptomatic endometriosis, Diabetes type 1 and 2, Malignant disease (excluding basalioma),
  • No history of: severe psychiatric disorder, alcohol or drug abuse, inflammatory bowel disease, microscopic colitis, diverticulitis or ileus, major abdominal surgery (except appendectomy, cholecystectomy, caesarean section, and hysterectomy)
  • No "red flags'' indicating severe undiagnosed disease: Night sweats (Repeated episodes of extreme perspiration that may soak nightclothes or bedding), Unintentional weight loss (≥ 4.5 kilograms, or 5% of normal body weight) over less than 6 months without knowing the reason, or blood in stool
  • Not pregnant
  • Ability to comply with protocol requirements

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

728 participants in 4 patient groups

Patient education
Sham Comparator group
Treatment:
Behavioral: Module 2
Behavioral: Module 3
Behavioral: Module 1
Behavioral therapy
Active Comparator group
Treatment:
Behavioral: Module 4
Behavioral: Module 2
Behavioral: Module 3
Behavioral: Module 1
Low FODMAP-diet
Active Comparator group
Treatment:
Behavioral: Module 2
Behavioral: Module 5
Behavioral: Module 3
Behavioral: Module 1
Combined treatment
Active Comparator group
Description:
Low FODMAP-diet and behavioral therapy
Treatment:
Behavioral: Module 4
Behavioral: Module 2
Behavioral: Module 5
Behavioral: Module 3
Behavioral: Module 1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems